Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Kiniksa Pharmaceuticals International reported significant financial results for Q4 and full year 2024, with ARCALYST® (rilonacept) net product revenues reaching $122.5 million for Q4 and $417 ...

ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 ...

From there, Ross Moat, our Chief Commercial Officer, will provide an update on our ongoing commercial execution with ARCALYST. Then, Mark Ragosa, our Chief Financial Officer, will review our ...

The sudden rise in the share price can be attributed to the positive investor expectations regarding the continued strong sales growth of Kiniksa’s only approved drug, Arcalyst (rilonacept).

The fact that over 2,550 prescribers have written Arcalyst prescriptions for recurrent pericarditis since the medication’s debut in April 2021 serves as proof of this. The average total length ...

I must say I did not expect much from Kiniksa this week as the company pre-announced Arcalyst net sales for the fourth quarter and full-year 2025 net sales guidance last month ahead of the ...

Since the launch of its approved drug ARCALYST in 2021 for recurrent pericarditis, Kiniksa has generated substantial revenue and aims to expand its influence in this market. The Chief Medical ...